A

Alliance Pharma PLC
LSE:APH

Watchlist Manager
Alliance Pharma PLC
LSE:APH
Watchlist
Price: 64.7 GBX Market Closed
Market Cap: £356.5m

Wall Street
Price Targets

APH Price Targets Summary
Alliance Pharma PLC

There are no price targets for APH.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Alliance Pharma PLC Competitors:
Price Targets
PACB
Pacific Biosciences of California Inc
11% Upside
FCBC
First Community Bankshares Inc
2% Upside
GTES
Gates Industrial Corporation PLC
20% Upside
SYSR
Systemair AB
14% Upside

Revenue
Forecast

10% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
10% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

For the last 14 years the compound annual growth rate for Alliance Pharma PLC's revenue is 10%. The projected CAGR for the next 3 years is 9%.

Operating Income
Forecast

4% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
4% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

For the last 14 years the compound annual growth rate for Alliance Pharma PLC's operating income is 4%. The projected CAGR for the next 3 years is 16%.

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-52%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-52%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is APH's stock price target?
Not Available

APH doesn't have any price targets made by Wall Street professionals.

What is Alliance Pharma PLC's Revenue forecast?
Projected CAGR
9%

For the last 14 years the compound annual growth rate for Alliance Pharma PLC's revenue is 10%. The projected CAGR for the next 3 years is 9%.

What is Alliance Pharma PLC's Operating Income forecast?
Projected CAGR
16%

For the last 14 years the compound annual growth rate for Alliance Pharma PLC's operating income is 4%. The projected CAGR for the next 3 years is 16%.

Back to Top